SG11201407652RA - Production cell line enhancers - Google Patents

Production cell line enhancers

Info

Publication number
SG11201407652RA
SG11201407652RA SG11201407652RA SG11201407652RA SG11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA
Authority
SG
Singapore
Prior art keywords
international
new york
production cell
edem2
cell
Prior art date
Application number
SG11201407652RA
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201407652RA publication Critical patent/SG11201407652RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
SG11201407652RA 2012-05-29 2013-05-29 Production cell line enhancers SG11201407652RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers
PCT/US2013/043116 WO2013181253A1 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (1)

Publication Number Publication Date
SG11201407652RA true SG11201407652RA (en) 2014-12-30

Family

ID=49670701

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201606654XA SG10201606654XA (en) 2012-05-29 2013-05-29 Production cell line enhancers
SG11201407652RA SG11201407652RA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201606654XA SG10201606654XA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Country Status (21)

Country Link
US (9) US9079954B2 (ru)
EP (3) EP3564262A1 (ru)
JP (5) JP6298455B2 (ru)
KR (4) KR102346867B1 (ru)
CN (2) CN110835624A (ru)
AU (4) AU2013267525B2 (ru)
BR (1) BR112014029095A2 (ru)
CA (1) CA2873131A1 (ru)
DK (1) DK2875047T5 (ru)
EA (2) EA201792213A1 (ru)
ES (1) ES2940900T3 (ru)
FI (1) FI2875047T3 (ru)
HK (1) HK1205137A1 (ru)
HU (1) HUE061479T2 (ru)
IL (3) IL235573B (ru)
MX (1) MX360359B (ru)
PL (1) PL2875047T3 (ru)
SG (2) SG10201606654XA (ru)
TW (2) TWI641687B (ru)
WO (1) WO2013181253A1 (ru)
ZA (1) ZA201408289B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
KR20230098361A (ko) 2016-04-20 2023-07-03 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
IL262268B2 (en) 2016-04-20 2024-05-01 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3541365A1 (en) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
CN111344410B (zh) 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
MXPA04011679A (es) 2002-05-29 2005-03-07 Regeneron Pharma Sistema de expresion eucariotico inducible.
AU2003268356A1 (en) 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
NZ544335A (en) * 2003-06-11 2009-01-31 Biogen Idec Inc Method to increase protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ES2673518T3 (es) * 2004-03-31 2018-06-22 Janssen Biotech, Inc. Métodos para modificar las tasas de producción de proteínas
ZA200701184B (en) 2004-07-20 2008-07-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
CA2577073C (en) 2004-09-02 2016-10-11 Wyeth Systems and methods for protein production employing polypeptides functional in unfolded protein response pathway
WO2006031931A2 (en) 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2129685B1 (en) 2007-03-21 2013-11-20 Danisco US Inc. Over expression of foldases and chaperones improves protein production
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CA2693504A1 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20110281301A1 (en) 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
ES2536644T3 (es) 2008-05-28 2015-05-27 Bayer Healthcare, Llc Procedimientos y composiciones para la producción de proteína recombinante en células de mamífero que expresan HBx
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) * 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
PL2808393T3 (pl) 2009-06-02 2018-04-30 Regeneron Pharmaceuticals, Inc. Komórki z brakiem fukozylacji
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
CN110787285A (zh) 2012-11-05 2020-02-14 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法

Also Published As

Publication number Publication date
EP4219546A2 (en) 2023-08-02
WO2013181253A1 (en) 2013-12-05
AU2021240303A1 (en) 2021-10-28
JP2022044609A (ja) 2022-03-17
DK2875047T5 (da) 2024-10-14
US10227401B2 (en) 2019-03-12
CN104350068A (zh) 2015-02-11
US20150299309A1 (en) 2015-10-22
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
KR20230065370A (ko) 2023-05-11
AU2013267525B2 (en) 2017-11-16
USRE48651E1 (en) 2021-07-20
KR20220003165A (ko) 2022-01-07
JP2018108094A (ja) 2018-07-12
AU2018201094B2 (en) 2019-06-20
EP3564262A1 (en) 2019-11-06
US10351622B2 (en) 2019-07-16
US20190270800A1 (en) 2019-09-05
EA028790B1 (ru) 2017-12-29
EA201492242A1 (ru) 2015-05-29
BR112014029095A2 (pt) 2017-07-18
US20150299310A1 (en) 2015-10-22
JP7382383B2 (ja) 2023-11-16
KR102126210B1 (ko) 2020-06-25
MX2014014630A (es) 2015-02-12
US9382315B2 (en) 2016-07-05
IL235573A0 (en) 2015-01-29
JP2020022514A (ja) 2020-02-13
US20160304598A1 (en) 2016-10-20
US9228012B2 (en) 2016-01-05
HUE061479T2 (hu) 2023-07-28
TW201402815A (zh) 2014-01-16
ES2940900T3 (es) 2023-05-12
KR102528950B1 (ko) 2023-05-08
IL279922A (en) 2021-03-01
EP2875047A1 (en) 2015-05-27
US20170291938A1 (en) 2017-10-12
KR20200074273A (ko) 2020-06-24
KR102346867B1 (ko) 2022-01-04
IL265867A (en) 2019-06-30
EP2875047B1 (en) 2023-01-25
HK1205137A1 (en) 2015-12-11
TW201823460A (zh) 2018-07-01
KR20150015492A (ko) 2015-02-10
US9688751B2 (en) 2017-06-27
US20150353634A1 (en) 2015-12-10
US20150175688A1 (en) 2015-06-25
US20130323788A1 (en) 2013-12-05
DK2875047T3 (da) 2023-03-27
US9193786B2 (en) 2015-11-24
CN104350068B (zh) 2019-12-03
JP2023153268A (ja) 2023-10-17
IL235573B (en) 2019-09-26
JP6622334B2 (ja) 2019-12-18
EP4219546A3 (en) 2023-08-23
SG10201606654XA (en) 2016-10-28
AU2013267525A1 (en) 2014-12-11
CN110835624A (zh) 2020-02-25
KR102663134B1 (ko) 2024-05-03
JP2015518728A (ja) 2015-07-06
AU2018201094A1 (en) 2018-03-15
JP7037535B2 (ja) 2022-03-16
EA201792213A1 (ru) 2018-01-31
AU2019203780A1 (en) 2019-06-20
JP6298455B2 (ja) 2018-03-20
FI2875047T3 (fi) 2023-03-30
US10611831B2 (en) 2020-04-07
ZA201408289B (en) 2016-09-28
MX360359B (es) 2018-10-30
CA2873131A1 (en) 2013-12-05
US9079954B2 (en) 2015-07-14
AU2019203780B2 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
SG11201407652RA (en) Production cell line enhancers
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201909777YA (en) Modulatory polynucleotides
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201909203WA (en) Tissue selective transgene expression
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201909011PA (en) Niraparib compositions
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201407774XA (en) Conversion of biomass
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201808398PA (en) Cell line for recombinant protein and/or viral vector production
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase